REXO5

Across TCGA pan-cancer cohorts, REXO5 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of REXO5’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where REXO5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types REXO5 is over-expressed in tumor, although a few such as KICH and BRCA show the opposite, repressed pattern.

KIRP, LIHC, and LUAD are the cancer types where REXO5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in REXO5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	II,III,IV	+0.845	<.001	11	view →
LIHC	Female	III,IV	+1.579	<.001	9	view →
LUAD	Male	All	+0.820	<.001	8	view →
COAD	Male	All	+0.765	<.001	8	view →
KIRC	Male	All	+0.506	<.001	8	view →
LUSC	Female	All	+1.275	<.001	7	view →
STAD	Male	II,III,IV	+0.928	<.001	6	view →
HNSC	Male	All	+0.508	.001	6	view →
BRCA	All	II,III,IV	+0.437	<.001	6	view →
CHOL	Male	All	+1.256	<.001	5	view →
THCA	All	All	+0.263	<.001	5	view →
KICH	Female	All	−0.955	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

REXO5–KIRP

Open the KIRP breakdown →